Loading
Trastuzumab pamirtecan is DualityBio and BioNTech's HER2 antibody-drug conjugate, in phase 3 trials in breast cancers with high and with modest HER2 expression and in HER2-expressing endometrial cancer.
DualityBio's DB-1303, licensed to BioNTech as BNT323, is a HER2-directed antibody-drug conjugate with a topoisomerase I inhibitor payload. Phase 3 trials are testing it in metastatic breast cancer with high and with modest HER2 expression against standard chemotherapy or other HER2 conjugates and in advanced HER2-expressing endometrial cancer, where it received US breakthrough designation. It is one of several conjugates trying to improve on trastuzumab deruxtecan's payload chemistry and tolerability.
A HER2 antibody carrying a topoisomerase I inhibitor payload through a cleavable linker, the same design family as trastuzumab deruxtecan, with a bystander effect on neighbouring cells. Connects to HER2.
1.Trastuzumab pamirtecan's antibody arm binds HER2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Trastuzumab pamirtecan" OR ABSTRACT:"Trastuzumab pamirtecan" OR TITLE:"DB-1303" OR ABSTRACT:"DB-1303" OR TITLE:"BNT323" OR ABSTRACT:"BNT323") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Trastuzumab pamirtecan, not a curated reading list.
Shares Duality Biotherapeutics, BioNTech and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech and the tag pipeline.
Shares Duality Biotherapeutics and the tag pipeline.
Shares Duality Biotherapeutics and the tag pipeline.
Shares Duality Biotherapeutics and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.